BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 17438043)

  • 1. Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations.
    Gumbo T; Louie A; Liu W; Brown D; Ambrose PG; Bhavnani SM; Drusano GL
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2329-36. PubMed ID: 17438043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isoniazid's bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium tuberculosis in the log phase of growth.
    Gumbo T; Louie A; Liu W; Ambrose PG; Bhavnani SM; Brown D; Drusano GL
    J Infect Dis; 2007 Jan; 195(2):194-201. PubMed ID: 17191164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamic evidence that ciprofloxacin failure against tuberculosis is not due to poor microbial kill but to rapid emergence of resistance.
    Gumbo T; Louie A; Deziel MR; Drusano GL
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3178-81. PubMed ID: 16048921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling.
    Gumbo T; Louie A; Deziel MR; Parsons LM; Salfinger M; Drusano GL
    J Infect Dis; 2004 Nov; 190(9):1642-51. PubMed ID: 15478070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The influence of human N-acetyltransferase genotype on the early bactericidal activity of isoniazid.
    Donald PR; Sirgel FA; Venter A; Parkin DP; Seifart HI; van de Wal BW; Werely C; van Helden PD; Maritz JS
    Clin Infect Dis; 2004 Nov; 39(10):1425-30. PubMed ID: 15546075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis.
    Jayaram R; Shandil RK; Gaonkar S; Kaur P; Suresh BL; Mahesh BN; Jayashree R; Nandi V; Bharath S; Kantharaj E; Balasubramanian V
    Antimicrob Agents Chemother; 2004 Aug; 48(8):2951-7. PubMed ID: 15273105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time-kill kinetics of anti-tuberculosis drugs, and emergence of resistance, in relation to metabolic activity of Mycobacterium tuberculosis.
    de Steenwinkel JE; de Knegt GJ; ten Kate MT; van Belkum A; Verbrugh HA; Kremer K; van Soolingen D; Bakker-Woudenberg IA
    J Antimicrob Chemother; 2010 Dec; 65(12):2582-9. PubMed ID: 20947621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biphasic kill curve of isoniazid reveals the presence of drug-tolerant, not drug-resistant, Mycobacterium tuberculosis in the guinea pig.
    Ahmad Z; Klinkenberg LG; Pinn ML; Fraig MM; Peloquin CA; Bishai WR; Nuermberger EL; Grosset JH; Karakousis PC
    J Infect Dis; 2009 Oct; 200(7):1136-43. PubMed ID: 19686043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutant prevention concentration of isoniazid, rifampicin and rifabutin against Mycobacterium tuberculosis.
    Rodríguez JC; Cebrián L; Ruiz M; López M; Royo G
    Chemotherapy; 2005 May; 51(2-3):76-9. PubMed ID: 15870500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of wild-type MIC distributions as a tool for determination of clinical breakpoints for Mycobacterium tuberculosis.
    Schön T; Juréen P; Giske CG; Chryssanthou E; Sturegård E; Werngren J; Kahlmeter G; Hoffner SE; Angeby KA
    J Antimicrob Chemother; 2009 Oct; 64(4):786-93. PubMed ID: 19633001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In silico children and the glass mouse model: clinical trial simulations to identify and individualize optimal isoniazid doses in children with tuberculosis.
    Jeena PM; Bishai WR; Pasipanodya JG; Gumbo T
    Antimicrob Agents Chemother; 2011 Feb; 55(2):539-45. PubMed ID: 21098246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early bactericidal activity of a moxifloxacin and isoniazid combination in smear-positive pulmonary tuberculosis.
    Gillespie SH; Gosling RD; Uiso L; Sam NE; Kanduma EG; McHugh TD
    J Antimicrob Chemother; 2005 Dec; 56(6):1169-71. PubMed ID: 16223939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efflux-pump-derived multiple drug resistance to ethambutol monotherapy in Mycobacterium tuberculosis and the pharmacokinetics and pharmacodynamics of ethambutol.
    Srivastava S; Musuka S; Sherman C; Meek C; Leff R; Gumbo T
    J Infect Dis; 2010 Apr; 201(8):1225-31. PubMed ID: 20210628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of correlation between embB mutation and ethambutol MIC in Mycobacterium tuberculosis clinical isolates from China.
    Shi R; Zhang J; Otomo K; Zhang G; Sugawara I
    Antimicrob Agents Chemother; 2007 Dec; 51(12):4515-7. PubMed ID: 17846128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of the role of Mycobacterium tuberculosis kasA gene mutations in isoniazid resistance.
    Sun YJ; Lee AS; Wong SY; Paton NI
    Clin Microbiol Infect; 2007 Aug; 13(8):833-5. PubMed ID: 17501974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid genotypic assays to identify drug-resistant Mycobacterium tuberculosis in South Africa.
    Evans J; Stead MC; Nicol MP; Segal H
    J Antimicrob Chemother; 2009 Jan; 63(1):11-6. PubMed ID: 18940875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacodynamics and pharmacokinetics of domestic fixed-dose combination of antituberculosis drugs].
    Zhao W; Li H; Duan L; Liang G; Zhang T; Lu Y
    Zhonghua Jie He He Hu Xi Za Zhi; 2002 Jun; 25(6):333-6. PubMed ID: 12126555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The early bactericidal activity of rifabutin measured by sputum viable counts in Hong Kong patients with pulmonary tuberculosis.
    Chan SL; Yew WW; Ma WK; Girling DJ; Aber VR; Felmingham D; Allen BW; Mitchison DA
    Tuber Lung Dis; 1992 Feb; 73(1):33-8. PubMed ID: 1326348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Understanding the action of INH on a highly INH-resistant Mycobacterium tuberculosis strain using Genechips.
    Fu LM; Shinnick TM
    Tuberculosis (Edinb); 2007 Jan; 87(1):63-70. PubMed ID: 16890025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Resistance-conferring mutations of Mycobacterium tuberculosis strains with low level resistance to isoniazid].
    Ano H; Matsumoto T; Nagai T; Tamura Y; Yoshida H; Kawahara K; Takamatsu I; Tsuyuguchi I; Takashima T
    Kekkaku; 2006 Dec; 81(12):709-13. PubMed ID: 17240915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.